Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.49, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 71.92% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 09/18/2023 | 71.92% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 05/18/2023 | 129.23% | Benchmark | → $8 | Reiterates | Speculative Buy → Speculative Buy |
| 02/14/2023 | 129.23% | Benchmark | $10 → $8 | Maintains | Speculative Buy |
| 07/27/2022 | 71.92% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 05/25/2021 | 329.8% | Benchmark | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年09月21日 | 71.92% | Maxim集團 | →$6 | 開始承保 | →購買 |
| 09/18/2023 | 71.92% | HC Wainwright公司 | →$6 | 開始承保 | →購買 |
| 2023年05月18日 | 129.23% | 基準 | →$8 | 重申 | 投機性買入→投機性買入 |
| 02/14/2023 | 129.23% | 基準 | $10→$8 | 維護 | 投機性購買 |
| 07/27/2022 | 71.92% | 拉登堡·塔爾曼 | →$6 | 開始承保 | →購買 |
| 2021/05/25 | 329.8% | 基準 | →$15 | 開始承保 | →購買 |
What is the target price for Anebulo Pharmaceuticals (ANEB)?
AneBulo製藥公司(ANEB)的目標價是多少？
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Maxim Group on September 21, 2023. The analyst firm set a price target for $6.00 expecting ANEB to rise to within 12 months (a possible 71.92% upside). 4 analyst firms have reported ratings in the last year.
MAXIM集團於2023年9月21日報道了安妮寶製藥(納斯達克：ANEB)的最新目標價。這家分析公司將目標價定為6.00美元，預計ANEB將在12個月內上漲至71.92%(可能上漲71.92%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?
分析師對安妮寶製藥(ANEB)的最新評級是多少？
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Maxim Group, and Anebulo Pharmaceuticals initiated their buy rating.
安妮寶製藥(納斯達克代碼：ANEB)的最新分析師評級是由Maxim Group提供的，安妮寶製藥啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?
AneBulo PharmPharmticals(ANEB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與AneBulo製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AneBulo製藥的上一次評級是在2023年9月21日提交的，所以你應該預計下一次評級將在2024年9月21日左右的某個時候公佈。
Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?
分析師對AneBulo製藥公司(ANEB)的評級正確嗎？
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.49, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的AneBulo PharmPharmticals(ANEB)評級是以0.00美元至6.00美元的目標價啟動的。AneBulo PharmPharmticals(ANEB)目前的交易價格為3.49美元，在分析師的預測範圍內。
